Michael Perry

Dr Michael Perry is senior vice president and chief scientific officer of Global Business Development and Licensing for Novartis AG. From 2014 to 2016, Dr Perry was chief scientific officer of Novartis’ Cell and Gene Therapy Unit, and from 2012 to 2014 was vice president and global head of Stem Cell Therapy for Novartis Pharmaceuticals Corp, a US affiliate of Switzerland-based Novartis AG. Dr Perry, based in the United States, was also global head of R&D at Baxter Healthcare, president and chief executive of Cell & Gene Therapy at Novartis affiliates Systemix and Genetic Therapy, vice president of regulatory affairs at Sandoz Pharmaceuticals, director of regulatory affairs at Schering-Plough Corporation, chair and chief executive of several early stage biotech companies. He also previously served as a Venture Partner with Bay City Capital, based in San Francisco California.
Bio last updated 02 Jun 2017

Access to our data for Michael Perry is only available to paid subscribers with access.

The search engine is Western Australia's most accurate and comprehensive business listings and searchable database.

Michael Perry is linked to 1 organisation which is included in 1 list - Public Companies - Industrial.

To see the data you will need to .

Total Shareholder Return as at 28/09/18

1 year TSR5 year TSR
107thAvita Medical78%-0%
223rdI Synergy Group31%0%
325thKatana Capital12%4%
349thMustera Property Group6%0%
739 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Source: Morningstar


Chief Executive Officer (from 2017); (Non-Executive Director 2013-2017)
Year started and most recent title


85th↑Mustera Property Group$11.4m
86th↑Avita Medical$11.3m
87th↑I Synergy Group$10.8m
88th↑Katana Capital$10.3m
239 listed industrial companies ranked by revenue.
Source: Morningstar

BNiQ Disclaimer